Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

• Published in: Journal of headache and pain Vol. 24; no. 1; pp. 30 - 12
• Main Authors: Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, Torelli, Paola, Finocchi, Cinzia, d’Onofrio, Florindo, d’Onofrio, Luigi, Rao, Renata, Messina, Stefano, Di Clemente, Laura, Ranieri, Angelo, Autunno, Massimo, Sette, Giuliano, Colombo, Bruno, Carnevale, Antonio, Aguggia, Marco, Tasillo, Miriam, Zoroddu, Francesco, Frediani, Fabio, Filippi, Massimo, Tomino, Carlo, Proietti, Stefania, Bonassi, Stefano
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 23.03.2023; Springer Nature B.V; BMC
• Subjects: Analgesics; CGRP monoclonal antibody; Disease prevention; Double-Blind Method; Fremanezumab; Headache; Humans; Internal Medicine; Long-term treatment; Medicine; Medicine & Public Health; Migraine; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; Migraine treatment; Monoclonal antibodies; Neurology; Pain Medicine; Prospective Studies; Real-word evidence of emerging therapies in headache; Real-world; Safety; Treatment Failure; Treatment Outcome; Fremanezumab; CGRP monoclonal antibody; Long-term treatment; Migraine treatment; Real-world

Background To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM: ≥ 8 days/month) or chronic migraine (CM: ≥ 15 days/month), and multiple preventive treatment failures. Methods This is a prospective, coh...